Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 9/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15076720 | 0.98 | L3MBTL3 (0.70) | L3MBTL3HPGDL3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL10720984 | 0.92 | HPGD (0.76) | L3MBTL3HPGDL3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL4252992 | 0.91 | L3MBTL3 (0.62) | L3MBTL3HPGDMAPK1SMN1; SMN2LMNA | |
| SCHEMBL7127339 | 0.90 | HPGD (0.77) | L3MBTL3HPGDL3MBTL1MAPK1SMN1; SMN2 | |
| Isophthalic Acid SCHEMBL27899309 | 0.87 | HPGD (0.61) | L3MBTL3HPGDSMN1; SMN2USP2MAPT | |
| SCHEMBL23682749 | 0.85 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1 | |
| SCHEMBL20267190 | 0.84 | SIGMAR1 (0.72) | L3MBTL3L3MBTL1MAPK1SMN1; SMN2LMNA | |
| SCHEMBL20267423 | 0.84 | MAPK1 (0.59) | L3MBTL3HPGDL3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL1199986 | 0.84 | L3MBTL1 (0.64) | L3MBTL3HPGDL3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL30577960 | 0.84 | L3MBTL1 (0.64) | L3MBTL3HPGDL3MBTL1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088108-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-06-14 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-110099905-A | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-06 | — | — | CN | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| CN-110088108-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| CN-110099905-A | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | disclosed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| CN-104016907-B | Amide compound, compositions and application thereof | EVOTEC GMBH (DE) | 2016-11-30 | — | — | CN | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| CN-100400523-C | Substituted piperazines, (1,4) diaza * class and 2, 5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LTD (GB) | 2008-07-09 | — | — | CN | disclosed |
| EP-1906964-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| CN-101070309-A | Substituted piperazines as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists, (1, 4) diazabi and 2, 5-diazabicyclo (2.2.1) heptanes | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | CN | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009741-A1 | PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
| CN-1726201-A | Substituted piperazines, (1,4) diaza * class and 2, 5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LTD (GB) | 2006-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275027-A1 | Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists | HRH3, HRH1, HRH4 | L3MBTL3 4311/4885HPGD 617/4885L3MBTL1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.